PET/CT and radiotherapy in prostate cancer

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 54, Issue 5, 2010, Pages 543-552

  De Jong, I J ^a   De Haan, T D ^b   Wiegman, E M ^a   Van Den Bergh, A C M ^a   Pruim, J ^a   Breeuwsma, A J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ISALA HOSPITAL   (Netherlands)

Author keywords

Positron emission tomography; Prostatic neoplasms; Radiotherapy; Tomography, X ray computed

Indexed keywords

CHOLINE C 11;

ADVANCED CANCER; ALGORITHM; ANDROGEN DEPRIVATION THERAPY; BLADDER WALL; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ASSESSMENT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; HUMAN; LYMPH NODE METASTASIS; MORPHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT CARE; PROSTATE CANCER; RECTUM; REVIEW; SALVAGE THERAPY; TREATMENT PLANNING;

HUMANS; MALE; NEOPLASM METASTASIS; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIOTHERAPY; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79251472484     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Smith JA Jr, Scardino PT, Resnick MI, Hernandez AD, Rose SC, Egger MJ. Transrectal ultrasound versus digital rectal examination for the staging of carcinoma of the prostate: results of a prospective, multi-institutional trial. J Urol 1997;157:902-6.
2. Hricak H, Dooms GC, Jeffrey RB, Avallone A, Jacobs D, Benton WK et al. Prostatic carcinoma: staging by clinical assessment, CT, and MR imaging. Radiology 1987;162:331-6.
3. Hovels AM, Heesakkers RA, Adang EM, Jager GJ, Strum S, Hoogeveen YL et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol 2008;63:387-95.
4. Harisinghani MG, Barentsz J, Hahn PF, Deserno WM, Tabatabaei S, van de Kaa CH et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003;348:2491-9.
5. Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006;65:965-74.
6. Sartor CI, Strawderman MH, Lin XH, Kish KE, McLaughlin PW, Sandler HM. Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy. Int J Radiat Oncol Biol Phys 1997;38:941-7.
7. Pisters LL, Perrotte P, Scott SM, Greene GF, von Eschenbach AC. Patient selection for salvage cryotherapy for locally recurrent prostate cancer after radiation therapy. J Clin Oncol 1999;17:2514-20.
8. Barocas DA, Han M, Epstein JI, Chan DY, Trock BJ, Walsh PC et al. Does capsular incision at radical retropubic prostatectomy affect disease-free survival in otherwise organ-confined prostate cancer? Urology 2001;58:746-51.
9. Martorana G, Schiavina R, Corti B, Farsad M, Salizzoni E, Brunocilla E et al. 11C-choline positron emission tomography/computerized tomography for tumor localization of primary prostate cancer in comparison with 12-core biopsy. J Urol 2006;176:954-60; discussion 960.
10. Farsad M, Schiavina R, Castellucci P, Nanni C, Corti B, Martorana G et al. Detection and localization of prostate cancer: correlation of (11)C-choline PET/CT with histopathologic step-section analysis. J Nucl Med 2005;46:1642-9.
11. Rinnab L, Blumstein NM, Mottaghy FM, Hautmann RE, Kufer R, Hohl K et al. 11C-choline positron-emission tomography/computed tomography and transrectal ultrasonography for staging localized prostate cancer. BJU Int 2007;99:1421-6.
12. Heicappell R, Muller-Mattheis V, Reinhardt M, Vosberg H, Gerharz CD, Muller-Gartner H et al. Staging of pelvic lymph nodes in neoplasms of the bladder and prostate by positron emission tomography with 2-[(18)F]-2-deoxy-D- glucose. Eur Urol 1999;36:582-7.
13. Sanz G, Robles JE, Gimenez M, Arocena J, Sanchez D, Rodriguez-Rubio F et al. Positron emission tomography with 18fluorine-labelled deoxyglucose: utility in localized and advanced prostate cancer. BJU Int 1999;84:1028-31.
14. Kanamaru H, Oyama N, Akino H, Okada K. Evaluation of prostate cancer using FDG-PET. Hinyokika Kiyo 2000;46:851-3.
15. Oyama N, Akino H, Kanamaru H, Suzuki Y, Muramoto S, Yonekura Y et al. 11C-acetate PET imaging of prostate cancer. J Nucl Med 2002;43:181-6.
16. Fricke E, Machtens S, Hofmann M, van den Hoff J, Bergh S, Brunkhorst T et al. Positron emission tomography with 11C-acetate and 18F-FDG in prostate cancer patients. Eur J Nucl Med Mol Imaging 2003;30:607-11.
17. Kotzerke J, Prang J, Neumaier B, Volkmer B, Guhlmann A, Kleinschmidt K et al. Experience with carbon-11 choline positron emission tomography in prostate carcinoma. Eur J Nucl Med 2000;27:1415-9.
18. de Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ. Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET. J Nucl Med 2003;44:331-5.
19. Schiavina R, Scattoni V, Castellucci P, Picchio M, Corti B, Briganti A et al. 11C-choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms. Eur Urol 2008;54:392-401.
20. Scher B, Seitz M, Albinger W, Tiling R, Scherr M, Becker HC et al. Value of 11C-choline PET and PET/CT in patients with suspected prostate cancer. Eur J Nucl Med Mol Imaging 2007;34:45-53.
21. Eschmann SM, Pfannenberg AC, Rieger A, Aschoff P, Muller M, Paulsen F et al. Comparison of 11C-choline-PET/CT and whole body-MRI for staging of prostate cancer. Nuklearmedizin 2007;46:161-8; quiz N47-8.
22. Beheshti M, Imamovic L, Broinger G, Vali R, Waldenberger P, Stoiber F et al. 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. Radiology 2010;254:925-33.
23. Steuber T, Schlomm T, Heinzer H, Zacharias M, Ahyai S, Chun KF et al. F(18)]-fluoroethylcholine combined in-line PET/CT scan for detection of lymph-node metastasis in high risk prostate cancer patients prior to radical prostatectomy: Preliminary results from a prospective histology-based study. Eur J Cancer 2010;46:449-55.
24. Lecouvet FE, Geukens D, Stainier A, Jamar F, Jamart J, d'Othee BJ et al. Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies. J Clin Oncol 2007;25:3281-7.
25. Lecouvet FE, Vande Berg BC, Malghem J, Omoumi P, Simoni P. Diffusion-weighted MR imaging: adjunct or alternative to T1-weighted MR imaging for prostate carcinoma bone metastases? Radiology 2009;252:624.
26. Yeh SD, Imbriaco M, Larson SM, Garza D, Zhang JJ, Kalaigian H et al. Detection of bony metastases of androgen-independent prostate cancer by PET-FDG. Nucl Med Biol 1996;23:693-7
27. Shreve PD, Grossman HB, Gross MD, Wahl RL. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. Radiology 1996;199:751-6.
28. Morris MJ, Akhurst T, Osman I, Nunez R, Macapinlac H, Siedlecki K et al. Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology 2002;59:913-8.
29. Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med 2006;47:287-97.
30. Even-Sapir E, Mishani E, Flusser G, Metser U. 18F-Fluoride positron emission tomography and positron emission tomography/computed tomography. Semin Nucl Med 2007;37:462-9.
31. Beheshti M, Vali R, Waldenberger P, Fitz F, Nader M, Hammer J et al. The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT. Mol Imaging Biol 2010;12:98-107.
32. Abuzallouf S, Dayes I, Lukka H. Baseline staging of newly diagnosed prostate cancer: a summary of the literature. J Urol 2004;171(6 Pt 1):2122-7.
33. Drever LA, Roa W, McEwan A, Robinson D. Comparison of three image segmentation techniques for target volume delineation in positron emission tomography. J Appl Clin Med Phys 2007;8:93-109.
34. Paulsen F, Scheiderbauer J, Eschmann SM, Brechtel K, Klein M, Pfannenberg C et al. First experiences of radiation treatment planning with PET/CT. Strahlenther Onkol 2006;182:369-75.
35. Wang H, Vees H, Miralbell R, Wissmeyer M, Steiner C, Ratib O et al. 18F-fluorocholine PET-guided target volume delineation techniques for partial prostate re-irradiation in local recurrent prostate cancer. Radiother Oncol 2009;93:220-5.
36. Pinkawa M, Attieh C, Piroth MD, Holy R, Nussen S, Klotz J et al. Dose-escalation using intensity-modulated radiotherapy for prostate cancer-evaluation of the dose distribution with and without 18F-choline PET/CT detected simultaneous integrated boost. Radiother Oncol 2009;93:213-9.
37. Niyazi M, Bartenstein P, Belka C, Ganswindt U. Choline PET based dose-painting in prostate cancer - modelling of dose effects. Radiat Oncol 2010;5:23.
38. Kotzerke J, Volkmer BG, Neumaier B, Gschwend JE, Hautmann RE, Reske SN. Carbon-11 acetate positron emission tomography can detect local recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 2002;29:1380-4.
39. de Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ. 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol 2003;44:32-8; discussion 38-9.
40. Breeuwsma AJ, Pruim J, van den Bergh AC, Leliveld AM, Nijman RJ, Dierckx RA et al. Detection of local, regional, and distant recurrence in patients with psa relapse after external-beam radiotherapy using (11)C-choline positron emission tomography. Int J Radiat Oncol Biol Phys 2010;77:160-4.
41. Schilling D, Schlemmer HP, Wagner PH, Bottcher P, Merseburger AS, Aschoff P et al. Histological verification of 11C-choline-positron emission/computed tomography-positive lymph nodes in patients with biochemical failure after treatment for localized prostate cancer. BJU Int 2008;102:446-51.
42. Picchio M, Messa C, Landoni C, Gianolli L, Sironi S, Brioschi M et al. Value of [11C]choline-positron emission tomography for restaging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography. J Urol 2003;169:1337-40.
43. Picchio M, Landoni C, Messa C, Gianolli L, Matarrese M, De Cobelli F et al. Positive [11C]choline and negative [18F]FDG with positron emission tomography in recurrence of prostate cancer. AJR Am J Roentgenol 2002;179:482-4.
44. Krause BJ, Souvatzoglou M, Tuncel M, Herrmann K, Buck AK, Praus C et al. The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 2008;35:18-23.
45. Husarik DB, Miralbell R, Dubs M, John H, Giger OT, Gelet A et al. Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer. Eur J Nucl Med Mol Imaging 2008;35:253-63.
46. Cimitan M, Bortolus R, Morassut S, Canzonieri V, Garbeglio A, Baresic T et al. 18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging 2006;33:1387-98.